163 related articles for article (PubMed ID: 32285106)
1. Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes†.
Li F; MacKenzie KR; Jain P; Santini C; Young DW; Matzuk MM
Biol Reprod; 2020 Aug; 103(2):427-436. PubMed ID: 32285106
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibition of BRDT for male contraception.
Matzuk MM; McKeown MR; Filippakopoulos P; Li Q; Ma L; Agno JE; Lemieux ME; Picaud S; Yu RN; Qi J; Knapp S; Bradner JE
Cell; 2012 Aug; 150(4):673-84. PubMed ID: 22901802
[TBL] [Abstract][Full Text] [Related]
4. A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR.
Huber AD; Poudel S; Wu J; Miller DJ; Lin W; Yang L; Bwayi MN; Rimmer MA; Gee RRF; Seetharaman J; Chai SC; Chen T
Nucleic Acids Res; 2024 Feb; 52(4):1661-1676. PubMed ID: 38084912
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
6. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
Jones Lipinski RA; Stancill JS; Nuñez R; Wynia-Smith SL; Sprague DJ; Nord JA; Bird A; Corbett JA; Smith BC
Am J Physiol Regul Integr Comp Physiol; 2024 Jun; 326(6):R515-R527. PubMed ID: 38618911
[TBL] [Abstract][Full Text] [Related]
7. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production.
Gibbons HR; Mi DJ; Farley VM; Esmond T; Kaood MB; Aune TM
Sci Rep; 2019 Jul; 9(1):10280. PubMed ID: 31311960
[TBL] [Abstract][Full Text] [Related]
10. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
11. BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy.
Guo M; Wang HX; Chen WJ
Toxicol Appl Pharmacol; 2018 Aug; 352():9-18. PubMed ID: 29782963
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
13. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
14. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
15. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.
Russell JO; Ko S; Saggi HS; Singh S; Poddar M; Shin D; Monga SP
Am J Pathol; 2018 Jun; 188(6):1389-1405. PubMed ID: 29545201
[TBL] [Abstract][Full Text] [Related]
18. Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.
Shaik AN; LeDuc BW; Khan AA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):827-834. PubMed ID: 28185143
[TBL] [Abstract][Full Text] [Related]
19. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
20. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.
Bid HK; Phelps DA; Xaio L; Guttridge DC; Lin J; London C; Baker LH; Mo X; Houghton PJ
Mol Cancer Ther; 2016 May; 15(5):1018-28. PubMed ID: 26908627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
